{"doc_id": "33781275", "type of study": "Therapy", "title": "", "abstract": "The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.\nOmega-3 polyunsaturated fatty acids (n3-PUFAs) may exert beneficial effects on the immune system of patients with viral infections.\nThis paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in critically ill patients with COVID-19.\nA double-blind, randomized clinical trial study was conducted on 128 critically ill patients infected with COVID-19 who were randomly assigned to the intervention (fortified formula with n3-PUFA) (n\u2009=\u200942) and control (n\u2009=\u200986) groups.\nData on 1\u00a0month survival rate, blood glucose, sodium (Na), potassium (K), blood urea nitrogen (BUN), creatinine (Cr), albumin, hematocrit (HCT), calcium (Ca), phosphorus (P), mean arterial pressure (MAP), O2 saturation (O2sat), arterial pH, partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2), bicarbonate (HCO3), base excess (Be), white blood cells (WBCs), Glasgow Coma Scale (GCS), hemoglobin (Hb), platelet (Plt), and the partial thromboplastin time (PTT) were collected at baseline and after 14\u00a0days of the intervention.\nThe intervention group had significantly higher 1-month survival rate and higher levels of arterial pH, HCO3, and Be and lower levels of BUN, Cr, and K compared with the control group after intervention (all P\u2009<\u20090.05).\nThere were no significant differences between blood glucose, Na, HCT, Ca, P, MAP, O2sat, PO2, PCO2, WBCs, GCS, Hb, Plt, PTT, and\u00a0albumin between two groups.\nOmega-3 supplementation improved the levels of several parameters of respiratory and renal function in critically ill patients with COVID-19.\nFurther clinical studies are warranted.\nTrial registry Name of the registry: This study was registered in the Iranian Registry of Clinical Trials (IRCT); Trial registration number: IRCT20151226025699N3; Date of registration: 2020.5.20; URL of trial registry record: https://en.irct.ir/trial/48213.\n", "Evidence Map": {"Enrollment": [{"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 128}, {"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 146}, {"term": "critically ill patients infected with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 116}, {"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 140}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19 : a randomized clinical trial .", "Evidence Elements": {"Participant": [{"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 128}], "Intervention": [{"term": "omega-3 fatty acid supplementation", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 48}], "Outcome": [{"term": "clinical and biochemical parameters", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 87}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Omega-3 polyunsaturated fatty acids ( n3-PUFAs ) may exert beneficial effects on the immune system of patients with viral infections .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "This paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in critically ill patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 146}], "Intervention": [{"term": "n3-PUFA supplementation", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 65}], "Outcome": [{"term": "inflammatory and biochemical markers", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 105}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A double-blind , randomized clinical trial study was conducted on 128 critically ill patients infected with COVID-19 who were randomly assigned to the intervention ( fortified formula with n3-PUFA ) ( n = 42 ) and control ( n = 86 ) groups .", "Evidence Elements": {"Participant": [{"term": "critically ill patients infected with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 116}], "Intervention": [{"term": "intervention", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 163}, {"term": "fortified formula with n3-PUFA", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 196}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Data on 1 month survival rate , blood glucose , sodium ( Na ) , potassium ( K ) , blood urea nitrogen ( BUN ) , creatinine ( Cr ) , albumin , hematocrit ( HCT ) , calcium ( Ca ) , phosphorus ( P ) , mean arterial pressure ( MAP ) , O2 saturation ( O2sat ) , arterial pH , partial pressure of oxygen ( PO2 ) , partial pressure of carbon dioxide ( PCO2 ) , bicarbonate ( HCO3 ) , base excess ( Be ) , white blood cells ( WBCs ) , Glasgow Coma Scale ( GCS ) , hemoglobin ( Hb ) , platelet ( Plt ) , and the partial thromboplastin time ( PTT ) were collected at baseline and after 14 days of the intervention .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "survival rate", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 29}, {"term": "blood glucose", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 45}, {"term": "sodium ( Na )", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 61}, {"term": "potassium ( K )", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 79}, {"term": "blood urea nitrogen ( BUN )", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 109}, {"term": "creatinine ( Cr )", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 129}, {"term": "albumin", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 139}, {"term": "hematocrit ( HCT )", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 160}, {"term": "calcium ( Ca )", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 177}, {"term": "phosphorus ( P )", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 196}, {"term": "mean arterial pressure ( MAP )", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 229}, {"term": "O2 saturation ( O2sat )", "negation": "affirmed", "UMLS": {}, "start": 232, "end": 255}, {"term": "arterial pH", "negation": "affirmed", "UMLS": {}, "start": 258, "end": 269}, {"term": "partial pressure of oxygen ( PO2 )", "negation": "affirmed", "UMLS": {}, "start": 272, "end": 306}, {"term": "partial pressure of carbon dioxide (", "negation": "affirmed", "UMLS": {}, "start": 309, "end": 345}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The intervention group had significantly higher 1-month survival rate and higher levels of arterial pH , HCO3 , and Be and lower levels of BUN , Cr , and K compared with the control group after intervention ( all P < 0.05 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intervention", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 16}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 174, "end": 181}, {"term": "after intervention", "negation": "affirmed", "UMLS": {}, "start": 188, "end": 206}], "Outcome": [{"term": "1-month survival rate", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 69}, {"term": "levels of arterial pH , HCO3 , and Be", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 118}, {"term": "levels of BUN , Cr , and K", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 155}], "Observation": [{"term": "significantly higher", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 47}, {"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 47}, {"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 128}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There were no significant differences between blood glucose , Na , HCT , Ca , P , MAP , O2sat , PO2 , PCO2 , WBCs , GCS , Hb , Plt , PTT , and albumin between two groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "blood glucose", "negation": "negated", "UMLS": {}, "start": 46, "end": 59}, {"term": "Na", "negation": "negated", "UMLS": {}, "start": 62, "end": 64}, {"term": "HCT", "negation": "negated", "UMLS": {}, "start": 67, "end": 70}, {"term": "Ca", "negation": "negated", "UMLS": {}, "start": 73, "end": 75}, {"term": "P", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 79}, {"term": "MAP", "negation": "negated", "UMLS": {}, "start": 82, "end": 85}, {"term": "O2sat", "negation": "negated", "UMLS": {}, "start": 88, "end": 93}, {"term": "PO2", "negation": "negated", "UMLS": {}, "start": 96, "end": 99}, {"term": "PCO2", "negation": "negated", "UMLS": {}, "start": 102, "end": 106}, {"term": "WBCs", "negation": "negated", "UMLS": {}, "start": 109, "end": 113}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 37}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significant differences", "Outcome": "blood glucose", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "Na", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "HCT", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "Ca", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "P", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "MAP", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "O2sat", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "PO2", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "PCO2", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "WBCs", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "Omega-3 supplementation improved the levels of several parameters of respiratory and renal function in critically ill patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "critically ill patients with COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 140}], "Intervention": [{"term": "Omega-3 supplementation", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23}], "Outcome": [{"term": "levels of several parameters of respiratory and renal function", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 99}], "Observation": [{"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 32}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Further clinical studies are warranted .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Trial registry Name of the registry : This study was registered in the Iranian Registry of Clinical Trials ( IRCT ) ; Trial registration number : IRCT20151226025699N3 ; Date of registration : 2020.5.20 ; URL of trial registry record : https:/ / en. irct.ir / trial / 48213 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}